骨肉瘤是一种原发性恶性骨肿瘤。对于难治性疾病有效的化疗方案很少，造成了生存率的没有改善。基于免疫的细胞治疗作为新颖的替代方案出现了。然而，这些疗法的进展主要取决于当免疫细胞武装以针对特定肿瘤抗原的情况下。近期的研究鉴定了临床上非常有前景的治疗靶点差异性分化簇 70（CD70）与骨肉瘤的关联，尤其是因为 CD70 在骨肉瘤肺转移中高度表达（Pahl et al. 2015. Cancer Cell Int. 15: 31），而且肿瘤对其的过表达与免疫逃逸和肿瘤增殖有关（Yang et al. 2007. Blood 110: 2537-2544）。然而，对于正常组织整体上 CD70 的表达的知识有限，以及偏离靶点效果的潜在风险产生了一些挑战（Flieswasser et al. 2022. J. Exp. Clin. Cancer Res. 41: 12）。尽管如此，基于 CD70 的临床试验目前正在进行中，并且初步显示出对于骨肉瘤患者有希望的结果。本综述文章对于近期与骨肉瘤相关的 CD70 文献进行了阐述，并强调了针对该途径的益处和挑战。© 2023 由美国免疫学家协会所有。

Osteosarcoma is a primary malignant bone tumor. Effective chemotherapy regimens for refractory disease are scarce, accounting for no improvement in survival. Immune-based cell therapies have emerged as novel alternatives. However, advancements with these therapies have been seen mostly when immune cells are armed to target specific tumor Ags. Recent studies identified cluster of differentiation 70 (CD70) as a promising target to osteosarcoma particularly because CD70 is highly expressed in osteosarcoma lung metastases (Pahl et al. 2015. Cancer Cell Int. 15: 31), and its overexpression by tumors has been correlated with immune evasion and tumor proliferation (Yang et al. 2007. Blood 110: 2537-2544). However, the limited knowledge of the overall CD70 expression within normal tissues and the potential for off-target effect pose several challenges (Flieswasser et al. 2022. J. Exp. Clin. Cancer Res. 41: 12). Nonetheless, CD70-based clinical trials are currently ongoing and are preliminarily showing promising results for patients with osteosarcoma. The present review sheds light on the recent literature on CD70 as it relates to osteosarcoma and highlights the benefits and challenges of targeting this pathway.Copyright © 2023 by The American Association of Immunologists, Inc.